問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3103Cases

2016-12-13 - 2017-10-30

Phase III

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) in Healthy Subjects Aged 3 Years Old to 17 Years Old

  • Condition/Disease

    Influenza

  • Test Drug

    Quadrivalent inactivated split (QIS) influenza vaccine (AdimFlu-S (QIS)

Participate Sites
2Sites

Terminated2Sites

2020-08-20 - 2021-05-06

Phase I

A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers

  • Condition/Disease

    COVID-19 prevention

  • Test Drug

    AdimrSC-2f (SARS-COV-2)

Participate Sites
1Sites

Recruiting1Sites

2021-01-01 - 2023-01-01

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2008-01-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2023-01-01 - 2025-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-01-01 - 2021-12-31

IIT

Others

Investigating clinical features and biomarkers of parkinsonism in CADASIL patients

  • Condition/Disease

    Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL)

  • Test Drug

    13N-NH3

Participate Sites
1Sites

Recruiting1Sites

2019-12-20 - 2024-08-16

IIT

Phase II

Regorafenib plus tislelizumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma (HCC)

  • Condition/Disease

    advanced hepatocellular carcinoma (HCC)

  • Test Drug

    1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)

Participate Sites
2Sites

Recruiting2Sites

2020-06-11 - 2022-11-02

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2022-12-21

IIT

Others

Multimodal biomarkers for diagnosis and prognosis in vascular cognitive impairment.

  • Condition/Disease

    Vascular Cognitive Impairment/Alzheimer Disease

  • Test Drug

    11C-PiB

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2020-10-01 - 2023-12-31

IIT

Phase II

Establishing 18F-PMPBB3 (APN-1607) PET imaging, genetic and plasma biomarkers for risk identification, disease progression and prognosis of tauopathy related Parkinsonism syndromes

  • Condition/Disease

    Parkinsonism syndromes

  • Test Drug

    18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)

Participate Sites
2Sites

Not yet recruiting2Sites

1 218 219 220 221 222 311
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB